SynthesisESC heart failure2024
A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.
Synthesis in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.ESC heart failure · 2024Pooled it
- Glycemic Variability as a Predictor of Mortality in Sepsis Patients With Concurrent Persistent Inflammation, Immunosuppression, and Catabolism Syndrome.Immunity, inflammation and disease · 2026Article
- Simultaneous assessment of stress hyperglycemia ratio and glucose variability to predict all-cause mortality in sepsis patients across different glucose metabolic states: an observational cohort study with interpretable machine learning approach.International journal of surgery (London, England) · 2026Observational
- In-Hospital Glycemic Variability and Mean Blood Glucose as Risk Markers for Long-Term Mortality in Patients with Diabetes.Journal of clinical medicine · 2025Article
- Heart Rate Variability as a Predictor of Mortality in Heart Failure: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Glycemic variability and postoperative mortality following cardiac surgery: evidence from a real-world ICU cohort.BMC cardiovascular disorders · 2025Observational
- Prognostic value of glycaemic variability for mortality in cardiogenic shock patients: a retrospective cohort study.Cardiovascular diabetology · 2025Article
- Association between triglyceride-glucose index trajectories and in-hospital mortality in sepsis: a cohort study based on the MIMIC-IV database.Lipids in health and disease · 2025Article
- Color-resolved third harmonic generation microscopy for single-RBC HbA1c measurement and glycemic history assessment.Science advances · 2025Article
- Prognostic effects of glycaemic variability on diastolic heart failure and type 2 diabetes mellitus: insights and 1-year mortality machine learning prediction model.Diabetology & metabolic syndrome · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent findings indicate that fluctuations in blood glucose could potentially increase the risk of unfavourable outcomes in individuals with cardiovascular conditions. The objective of the research was to assess the correlation between glycaemic variability (GV) and the mortality of patients with heart failure (HF) through a comprehensive review and meta-analysis. Longitudinal follow-up studies comparing the mortality risk between HF patients with higher and lower GV were identified by searching Medline, Embase, Web of Science, and Cochrane Library databases. The results were combined using a random-effects model that accounted for the potential variability. The meta-analysis included nine cohort studies involving 76 843 patients diagnosed with HF, out of which 35 853 patients died within a follow-up period of up to 86 months. The combined findings indicated that a significant increase in GV was linked to an elevated risk of mortality in patients with HF during the follow-up period (RR 2.18, 95% CI 1.61 to 2.96, P < 0.001, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.